Response Genetics, Knight Diagnostic Labs Reach Deal to Launch NGS-based Lung Cancer Panel | GenomeWeb

NEW YORK (GenomeWeb) – Response Genetics today said it has executed a commercial agreement with the Knight Diagnostic Laboratories at Oregon Health & Science University to launch a next-generation sequencing-based lung cancer panel.

The Knight Diagnostic-developed panel provides "full gene sequencing of the actionable genes for lung cancer rather than detection only of so-called hot spots," Response Genetics said. It added that it expects to market the panel immediately.

Financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.